Protagonist Therapeutics, Inc. (PTGX)
154.70
+0.38
(+0.25%)
USD |
NASDAQ |
Aug 24, 16:00
154.70
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Enterprise Value : 9.207B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 9.207B |
| August 20, 2026 | 8.972B |
| August 19, 2026 | 9.247B |
| August 18, 2026 | 9.402B |
| August 17, 2026 | 9.485B |
| August 14, 2026 | 9.257B |
| August 13, 2026 | 9.019B |
| August 12, 2026 | 9.057B |
| August 11, 2026 | 8.817B |
| August 10, 2026 | 8.927B |
| August 07, 2026 | 8.660B |
| August 06, 2026 | 8.680B |
| August 05, 2026 | 8.107B |
| August 04, 2026 | 8.010B |
| August 03, 2026 | 7.781B |
| July 31, 2026 | 8.063B |
| July 30, 2026 | 8.193B |
| July 29, 2026 | 7.828B |
| July 28, 2026 | 8.076B |
| July 27, 2026 | 7.994B |
| July 24, 2026 | 8.029B |
| July 23, 2026 | 7.985B |
| July 22, 2026 | 7.986B |
| July 21, 2026 | 8.171B |
| July 20, 2026 | 7.910B |
| Date | Value |
|---|---|
| July 17, 2026 | 8.340B |
| July 16, 2026 | 7.765B |
| July 15, 2026 | 7.987B |
| July 14, 2026 | 7.716B |
| July 13, 2026 | 7.627B |
| July 10, 2026 | 7.726B |
| July 09, 2026 | 8.128B |
| July 08, 2026 | 8.285B |
| July 07, 2026 | 8.336B |
| July 06, 2026 | 7.731B |
| July 02, 2026 | 7.739B |
| July 01, 2026 | 7.322B |
| June 30, 2026 | 7.154B |
| June 29, 2026 | 7.274B |
| June 26, 2026 | 7.290B |
| June 25, 2026 | 7.338B |
| June 24, 2026 | 7.307B |
| June 23, 2026 | 7.102B |
| June 22, 2026 | 6.850B |
| June 18, 2026 | 6.711B |
| June 17, 2026 | 6.619B |
| June 16, 2026 | 6.568B |
| June 15, 2026 | 6.685B |
| June 12, 2026 | 6.513B |
| June 11, 2026 | 6.513B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 202.61B |
| Insmed, Inc. | 27.04B |
| Madrigal Pharmaceuticals, Inc. | 11.44B |
| AbbVie, Inc. | 532.50B |
| PTC Therapeutics, Inc. | 4.285B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 162.85M |
| Revenue (Quarterly) | 213.48M |
| Total Expenses (Quarterly) | 50.63M |
| EPS Diluted (Quarterly) | 2.293 |
| Gross Profit Margin (Quarterly) | 99.81% |
| Profit Margin (Quarterly) | 76.28% |
| Earnings Yield | 0.67% |
| Operating Earnings Yield | 0.56% |
| Normalized Earnings Yield | 0.6703 |